Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of “Moderate Buy” by Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned an average rating of “Moderate Buy” from the thirteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $40.6250.

ROIV has been the subject of several research reports. Guggenheim upped their target price on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Tuesday, August 25th. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. TD Cowen upped their price objective on shares of Roivant Sciences from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th.

Roivant Sciences Stock Down 0.3%

Shares of ROIV stock opened at $40.82 on Friday. The business has a 50-day moving average price of $35.79 and a two-hundred day moving average price of $31.62. Roivant Sciences has a 12-month low of $13.81 and a 12-month high of $42.50. The firm has a market cap of $29.49 billion, a P/E ratio of -77.02 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, research analysts expect that Roivant Sciences will post -2 EPS for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other news, insider Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88. Following the transaction, the insider owned 18,630,739 shares in the company, valued at approximately $679,649,358.72. The trade was a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Gold sold 12,380 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total value of $436,766.40. Following the completion of the sale, the director directly owned 13,689,166 shares of the company’s stock, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,055,913 shares of company stock valued at $107,261,258. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its position in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after buying an additional 34,341 shares during the period. American Century Companies Inc. increased its stake in shares of Roivant Sciences by 1.9% in the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after buying an additional 1,689 shares during the period. Russell Investments Group Ltd. raised its holdings in Roivant Sciences by 149.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock valued at $129,000 after buying an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp raised its holdings in Roivant Sciences by 10.2% during the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after buying an additional 1,181 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.